NASDAQ:EXA - EXA Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$24.24 0.00 (0.00 %)
(As of 05/23/2018 05:15 AM ET)
Previous Close$24.2350
Today's Range$24.24 - $24.24
52-Week Range$12.34 - $24.42
VolumeN/A
Average Volume100,740 shs
Market Capitalization$363.92 million
P/E RatioN/A
Dividend YieldN/A
Beta0.63

About EXA (NASDAQ:EXA)

EXA logoExa Corporation develops, sells and supports simulation software and services that manufacturers use in design and engineering processes. The Company focuses primarily on the ground transportation market, including manufacturers in the passenger vehicle, highway truck, off-highway vehicle and train markets, as well as their suppliers. Its product, PowerFLOW, is a software solution for simulating fluid flow problems, including aerodynamics, thermal management and aeroacoustics, or wind noise. PowerFLOW uses its Digital Physics technology that enables it to predict fluid flows. PowerFLOW directly simulates unpredictable turbulent scales. The PowerFLOW software suite includes the simulation engine and grid generation engine, along with pre- and post-processing software products. The software is delivered in client/server architecture, or through its cloud-based offering, ExaCLOUD. With the ExaCLOUD solution, various client features and functions are accessed through a Web browser.

Receive EXA News and Ratings via Email

Sign-up to receive the latest news and ratings for EXA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryApplication Software
SectorN/A
SymbolNASDAQ:EXA
CUSIP30061450
Phone+1-781-6768500

Debt

Debt-to-Equity Ratio0.01
Current Ratio1.06
Quick Ratio1.06

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$72.58 million
Price / Sales5.04
Cash Flow$0.2132 per share
Price / Cash113.69
Book Value$1.29 per share
Price / Book18.79

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-1,130,000.00
Net Margins-15.10%
Return on Equity-62.82%
Return on Assets-18.57%

Miscellaneous

Employees345
Outstanding Shares15,100,000

EXA (NASDAQ:EXA) Frequently Asked Questions

What is EXA's stock symbol?

EXA trades on the NASDAQ under the ticker symbol "EXA."

How were EXA's earnings last quarter?

Exa Corp (NASDAQ:EXA) posted its quarterly earnings data on Wednesday, May, 24th. The technology company reported ($0.14) EPS for the quarter, topping the Zacks' consensus estimate of ($0.18) by $0.04. The technology company earned $16.56 million during the quarter, compared to the consensus estimate of $16.56 million. EXA had a negative net margin of 15.10% and a negative return on equity of 62.82%. The company's quarterly revenue was down 1.4% on a year-over-year basis. During the same period in the prior year, the business posted ($0.04) EPS. View EXA's Earnings History.

What price target have analysts set for EXA?

4 equities research analysts have issued twelve-month price targets for EXA's stock. Their predictions range from $24.25 to $24.25. On average, they anticipate EXA's stock price to reach $24.25 in the next year. View Analyst Ratings for EXA.

Who are EXA's key executives?

EXA's management team includes the folowing people:
  • John J. Shields III, Independent Chairman of the Board (Age 76)
  • Stephen A. Remondi, President, Chief Executive Officer, Director (Age 50)
  • Richard F. Gilbody, Chief Financial Officer (Age 55)
  • Hudong Chen Ph.D., Senior Vice President, Chief Scientific Officer (Age 58)
  • Suresh Sundaram, Senior Vice President, Products and Marketing
  • James E Hoch, Senior Vice President - Software Development (Age 50)
  • Joel F. Dube, Principal Accounting Officer, Vice President - Finance
  • Jean-Paul Roux, Vice President - European Operations (Age 51)
  • Robert D. Burke, Independent Director (Age 60)
  • Mark E. Fusco, Independent Director (Age 52)

Has EXA been receiving favorable news coverage?

Media stories about EXA stock have trended somewhat positive this week, Accern reports. Accern scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. EXA earned a coverage optimism score of 0.15 on Accern's scale. They also gave media stories about the technology company an impact score of 46.02 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.

How do I buy shares of EXA?

Shares of EXA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is EXA's stock price today?

One share of EXA stock can currently be purchased for approximately $24.24.

How big of a company is EXA?

EXA has a market capitalization of $363.92 million and generates $72.58 million in revenue each year. EXA employs 345 workers across the globe.

How can I contact EXA?

EXA's mailing address is 55 Network Dr, BURLINGTON, MA 01803-2756, United States. The technology company can be reached via phone at +1-781-6768500 or via email at [email protected]


MarketBeat Community Rating for EXA (EXA)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  173 (Vote Outperform)
Underperform Votes:  128 (Vote Underperform)
Total Votes:  301
MarketBeat's community ratings are surveys of what our community members think about EXA and other stocks. Vote "Outperform" if you believe EXA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EXA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

EXA (NASDAQ:EXA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for EXA in the last 12 months. Their average twelve-month price target is $24.25, suggesting that the stock has a possible upside of 0.04%. The high price target for EXA is $24.25 and the low price target for EXA is $24.25. There are currently 4 hold ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.002.002.00
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $24.25$24.25$20.6250$20.6250
Price Target Upside: 0.04% upside0.29% upside14.70% downside14.70% downside

EXA (NASDAQ:EXA) Consensus Price Target History

Price Target History for EXA (NASDAQ:EXA)

EXA (NASDAQ:EXA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/29/2017Needham & Company LLCDowngradeBuy ➝ HoldLowView Rating Details
9/28/2017Canaccord GenuityReiterated RatingHold$24.25LowView Rating Details
9/28/2017Stifel NicolausDowngradeBuy ➝ Hold$17.00 ➝ $24.25LowView Rating Details
9/28/2017Robert W. BairdDowngradeOutperform ➝ NeutralLowView Rating Details
(Data available from 5/23/2016 forward)

Earnings

EXA (NASDAQ:EXA) Earnings History and Estimates Chart

Earnings by Quarter for EXA (NASDAQ:EXA)

EXA (NASDAQ:EXA) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.34 EPS
Next Year EPS Consensus Estimate: $-0.09 EPS

EXA (NASDAQ EXA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/28/2017Q2 2018($0.12)($0.12)$17.58 million$17.50 millionViewN/AView Earnings Details
5/24/2017Q1 2018($0.18)($0.14)$16.56 million$16.56 millionViewN/AView Earnings Details
3/16/2017Q4 2017($0.0020)$0.03$20.25 million$19.53 millionViewN/AView Earnings Details
11/30/2016Q3 2017($0.01)$0.04$19.10 million$19.20 millionViewN/AView Earnings Details
8/29/2016Q217($0.06)($0.02)$17.32 million$17.11 millionViewListenView Earnings Details
5/25/2016Q1($0.08)($0.04)$16.68 million$16.80 millionViewListenView Earnings Details
3/10/2016Q416($0.15)($0.06)$17.72 million$18.30 millionViewListenView Earnings Details
12/3/2015Q316($0.05)($0.03)$16.87 million$17.00 millionViewListenView Earnings Details
9/1/2015Q216($0.08)($0.06)$15.53 million$15.50 millionViewListenView Earnings Details
5/28/2015Q116($0.14)($0.10)$14.65 million$14.80 millionViewListenView Earnings Details
3/19/2015Q415($0.01)($0.04)$16.74 million$16.86 millionViewN/AView Earnings Details
12/4/2014Q315$0.03$0.04$16.20 million$15.96 millionViewN/AView Earnings Details
8/27/2014Q215($0.03)($0.06)$14.48 million$14.80 millionViewN/AView Earnings Details
5/29/2014Q115($0.04)($1.27)$13.94 million$13.80 millionViewN/AView Earnings Details
3/24/2014Q414$0.03$0.03$14.70 million$15.20 millionViewN/AView Earnings Details
12/4/2013Q3$0.04$0.05$13.72 million$14.10 millionViewListenView Earnings Details
9/4/2013Q2 2014($0.04)($0.04)$13.08 million$12.70 millionViewN/AView Earnings Details
6/4/2013Q1 2014($0.04)($0.02)$12.17 million$12.50 millionViewN/AView Earnings Details
3/27/2013Q4 2013$0.03($0.01)$12.32 million$13.10 millionViewN/AView Earnings Details
12/3/20120.00$0.02$12.70 millionViewN/AView Earnings Details
9/6/2012Q213$0.02$0.10$11.89 million$11.80 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

EXA (NASDAQ:EXA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

EXA (NASDAQ EXA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 11.53%
Institutional Ownership Percentage: 74.37%
Insider Trading History for EXA (NASDAQ:EXA)
Insider Trading History for EXA (NASDAQ:EXA)

EXA (NASDAQ EXA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/26/2017Soros Fund Management LlcMajor ShareholderBuy14,119$16.58$234,093.02View SEC Filing  
9/25/2017Soros Fund Management LlcMajor ShareholderBuy700$16.15$11,305.00View SEC Filing  
9/21/2017Soros Fund Management LlcMajor ShareholderBuy15,489$15.99$247,669.11View SEC Filing  
9/18/2017Soros Fund Management LlcMajor ShareholderBuy53,502$15.49$828,745.98View SEC Filing  
9/13/2017Soros Fund Management LlcMajor ShareholderBuy159,500$14.46$2,306,370.00View SEC Filing  
6/1/2017John J ShieldsDirectorSell1,000$13.89$13,890.0053,078View SEC Filing  
5/1/2017John J ShieldsDirectorSell1,000$13.75$13,750.0054,078View SEC Filing  
4/3/2017John J ShieldsDirectorSell1,000$12.80$12,800.0055,078View SEC Filing  
3/1/2017John J ShieldsDirectorSell1,000$15.74$15,740.0056,078View SEC Filing  
2/1/2017John J ShieldsDirectorSell1,000$15.60$15,600.0057,078View SEC Filing  
1/3/2017John J ShieldsDirectorSell1,000$15.33$15,330.0058,078View SEC Filing  
12/20/2016Hudong ChenInsiderSell3,000$16.00$48,000.00119,656View SEC Filing  
12/20/2016James E HochVPSell12,000$16.00$192,000.00153,694View SEC Filing  
12/1/2016John J ShieldsDirectorSell1,000$15.00$15,000.0059,078View SEC Filing  
11/1/2016John J ShieldsDirectorSell1,000$14.00$14,000.0060,078View SEC Filing  
10/7/2016Wayne D MackieDirectorBuy10,565$14.91$157,524.1569,723View SEC Filing  
10/6/2016Fidelity Non-Profit ManagementMajor ShareholderSell1,200,000$14.72$17,664,000.00905,640View SEC Filing  
10/3/2016John J ShieldsDirectorSell1,000$16.03$16,030.0061,078View SEC Filing  
9/1/2016John J ShieldsDirectorSell1,000$15.62$15,620.0062,778View SEC Filing  
8/1/2016John J ShieldsDirectorSell2,000$14.37$28,740.0064,078View SEC Filing  
7/25/2016John J ShieldsDirectorSell4,699$13.96$65,598.0465,078View SEC Filing  
7/1/2016Stephen A RemondiCEOSell10,000$14.45$144,500.00356,974View SEC Filing  
6/6/2016Stephen A RemondiCEOSell4,001$11.52$46,091.52369,974View SEC Filing  
6/3/2016Stephen A RemondiCEOSell5,999$11.84$71,028.16375,361View SEC Filing  
5/4/2016Stephen A RemondiCEOSell10,000$13.07$130,700.00383,732View SEC Filing  
5/3/2016Stephen A RemondiCEOSell3,363$13.09$44,021.67383,732View SEC Filing  
5/2/2016Stephen A RemondiCEOSell3,242$13.20$42,794.40383,732View SEC Filing  
4/4/2016Stephen A RemondiCEOSell10,000$12.94$129,400.00393,120View SEC Filing  
3/21/2016Hudong ChenVPSell20,000$12.01$240,200.0074,426View SEC Filing  
3/14/2016James E HochVPSell8,000$11.50$92,000.0096,464View SEC Filing  
3/1/2016Stephen A RemondiCEOSell10,000$10.64$106,400.00401,974View SEC Filing  
2/24/2016Hudong ChenVPSell10,000$10.61$106,100.00105,926View SEC Filing  
2/2/2016Stephen A. RemondiCEOSell10,000$10.76$107,600.00406,974View SEC Filing  
1/8/2016James E HochVPSell4,000$11.50$46,000.00104,464View SEC Filing  
1/5/2016Stephen A. RemondiCEOSell10,000$11.57$115,700.00416,974View SEC Filing  
1/5/2016Wayne D MackieDirectorBuy5,000$11.58$57,900.0065,148View SEC Filing  
1/4/2016Stephen A. RemondiCEOSell2,754$11.46$31,560.84416,974View SEC Filing  
12/31/2015James E. HochVPSell4,000$11.50$46,000.00108,464View SEC Filing  
12/22/2015Stephen A. RemondiCEOSell10,000$11.00$110,000.00426,974View SEC Filing  
12/21/2015Richard F. GilbodyCFOBuy10,000$10.92$109,200.0020,000View SEC Filing  
12/16/2015Wayne D. MackieDirectorBuy3,375$10.44$35,235.0054,713View SEC Filing  
12/15/2015Wayne D. MackieDirectorBuy10,000$10.08$100,800.0054,713View SEC Filing  
12/14/2015Wayne D. MackieDirectorBuy3,175$10.09$32,035.7554,713View SEC Filing  
11/3/2015Stephen A. RemondiCEOSell10,000$9.68$96,800.00436,974View SEC Filing  
10/7/2015Stephen A. RemondiCEOSell10,000$10.02$100,200.00446,974View SEC Filing  
10/6/2015Stephen A. RemondiCEOSell6,623$10.00$66,230.00446,974View SEC Filing  
10/5/2015Stephen A. RemondiCEOSell800$10.15$8,120.00446,974View SEC Filing  
9/2/2015Stephen A RemondiCEOSell10,000$10.51$105,100.00456,974View SEC Filing  
7/6/2015Stephen A RemondiCEOSell10,000$11.06$110,600.00View SEC Filing  
6/11/2015John J ShieldsDirectorSell4,600$11.36$52,256.00View SEC Filing  
6/9/2015John J ShieldsDirectorSell5,400$11.50$62,100.00View SEC Filing  
6/4/2015Stephen A RemondiCEOSell10,000$10.85$108,500.00View SEC Filing  
5/5/2015Stephen A RemondiCEOSell8,884$10.94$97,190.96View SEC Filing  
4/16/2015Wayne D MackieDirectorBuy12,000$10.79$129,480.00View SEC Filing  
4/2/2015Stephen A RemondiCEOSell10,000$11.64$116,400.00View SEC Filing  
3/9/2015Stephen A RemondiCEOSell6,423$10.00$64,230.00View SEC Filing  
3/6/2015Stephen A RemondiCEOSell3,577$10.16$36,342.32View SEC Filing  
2/9/2015Stephen A RemondiCEOSell4,802$10.23$49,124.46View SEC Filing  
2/4/2015Stephen A RemondiCEOSell5,198$10.22$53,123.56View SEC Filing  
2/3/2015Stephen A RemondiCEOSell1,489$10.21$15,202.69View SEC Filing  
2/2/2015Stephen A RemondiCEOSell2,109$10.24$21,596.16View SEC Filing  
1/9/2015Stephen A RemondiCEOSell10,000$10.79$107,900.00View SEC Filing  
12/22/2014Stephen A RemondiCEOSell10,000$11.12$111,200.00View SEC Filing  
11/6/2014Stephen A RemondiCEOSell10,000$9.97$99,700.00View SEC Filing  
10/1/2014Stephen A RemondiCEOSell10,000$11.30$113,000.00View SEC Filing  
9/2/2014Stephen A RemondiCEOSell10,000$12.02$120,200.00View SEC Filing  
8/1/2014Stephen A RemondiCEOSell10,000$9.25$92,500.00View SEC Filing  
7/1/2014Stephen A RemondiCEOSell10,000$11.11$111,100.00View SEC Filing  
6/17/2014Jean-Paul RouxVPBuy2,000$9.44$18,880.00View SEC Filing  
6/9/2014John William Sr Poduska SrDirectorBuy2,793$8.90$24,857.70View SEC Filing  
6/4/2014Stephen A RemondiCEOSell10,000$9.12$91,200.00View SEC Filing  
5/1/2014Stephen RemondiCEOSell10,000$10.90$109,000.00182,359View SEC Filing  
4/10/2014Stephen SarnoCFOBuy1,000$11.98$11,980.0016,000View SEC Filing  
4/4/2014John William Sr Poduska, Sr.DirectorBuy1,600$12.71$20,336.0047,207View SEC Filing  
4/4/2014Stephen RemondiCEOSell2,500$12.72$31,800.00192,359View SEC Filing  
4/3/2014Stephen RemondiCEOSell7,500$13.13$98,475.00194,859View SEC Filing  
4/1/2014John William Sr Poduska, Sr.DirectorBuy1,000$13.31$13,310.0046,607View SEC Filing  
3/28/2014John William Sr Poduska, Sr.DirectorBuy6,300$13.39$84,357.0045,607View SEC Filing  
3/25/2014James HochVPSell1,300$15.75$20,475.0035,541View SEC Filing  
3/4/2014Stephen RemondiCEOSell10,000$14.75$147,500.0052,359View SEC Filing  
1/6/2014Stephen RemondiCEOSell10,000$13.31$133,100.0072,359View SEC Filing  
12/20/2013Stephen RemondiCEOSell10,000$13.08$130,800.0082,359View SEC Filing  
12/17/2013John William Sr Poduska, Sr.DirectorBuy4,607$13.53$62,332.7141,607View SEC Filing  
10/2/2013Jean-Paul RouxVPBuy2,000$15.17$30,340.00130,289View SEC Filing  
10/2/2013Stephen A RemondiCEOSell10,000$15.14$151,400.00View SEC Filing  
9/18/2013John William Sr Poduska, Sr.DirectorBuy11,821$15.62$184,644.0239,000View SEC Filing  
9/13/2013John William Sr Poduska, Sr.DirectorBuy6,170$13.96$86,133.2031,009View SEC Filing  
9/4/2013Stephen A RemondiCEOSell10,000$13.78$137,800.00View SEC Filing  
8/2/2013Stephen RemondiCEOSell10,000$11.50$115,000.00112,359View SEC Filing  
7/12/2013John William Sr Poduska SrDirectorBuy5,009$10.26$51,392.34View SEC Filing  
7/2/2013Stephen A RemondiCEOSell10,000$10.61$106,100.00View SEC Filing  
6/3/2013Stephen A RemondiCEOSell10,000$8.32$83,200.00View SEC Filing  
4/9/2013John William Sr Poduska SrDirectorBuy6,000$7.55$45,300.00View SEC Filing  
4/8/2013Stephen P SarnoInsiderBuy5,000$7.50$37,500.00View SEC Filing  
4/5/2013Edmond L FurlongCFOBuy10,000$7.55$75,500.00View SEC Filing  
4/4/2013John F Smith JrDirectorBuy4,000$8.10$32,400.00View SEC Filing  
2/1/2013Stephen A RemondiCEOSell10,000$9.81$98,100.00View SEC Filing  
1/17/2013Edmond L FurlongCFOBuy15,998$9.95$159,180.10View SEC Filing  
1/11/2013Edmond L FurlongCFOBuy5,973$9.57$57,161.61View SEC Filing  
1/9/2013Stephen P SarnoInsiderBuy10,000$9.34$93,400.00View SEC Filing  
1/4/2013John William Sr Poduska SrDirectorBuy20,000$9.73$194,600.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

EXA (NASDAQ EXA) News Headlines

Source:
DateHeadline
Innoplexus Releases New Study Examining Consumer Perceptions of Pharmaceutical CompaniesInnoplexus Releases New Study Examining Consumer Perceptions of Pharmaceutical Companies
www.prnewswire.com - May 17 at 7:49 AM
The 30-Year View: Examining the Future of GoldThe 30-Year View: Examining the Future of Gold
www.prnewswire.com - May 17 at 3:36 AM
Here Is the Exact Amount of Money You Need to Be Considered ‘Wealthy’ in AmericaHere Is the Exact Amount of Money You Need to Be Considered ‘Wealthy’ in America
finance.yahoo.com - May 16 at 2:46 PM
Cloud Native Computing Foundation Announces Launch of Certified Kubernetes Application Developer (CKAD) ExamCloud Native Computing Foundation Announces Launch of Certified Kubernetes Application Developer (CKAD) Exam
www.prnewswire.com - May 2 at 3:48 AM
Exact Sciences to participate in two investor conferences during MayExact Sciences to participate in two investor conferences during May
www.prnewswire.com - May 1 at 6:08 AM
Why Exact Sciences Is Soaring TodayWhy Exact Sciences Is Soaring Today
www.fool.com - April 27 at 1:43 PM
Exact Sciences Q1 revenue up 87%; shares up 1% after hoursExact Sciences Q1 revenue up 87%; shares up 1% after hours
seekingalpha.com - April 26 at 4:32 PM
Kathys Urgent Care Offering More Affordable DOT/CDL Physical ExamsKathy's Urgent Care Offering More Affordable DOT/CDL Physical Exams
www.prnewswire.com - April 23 at 11:32 AM
Study Examines Maternal Metabolic Factors and Early-Onset PubertyStudy Examines Maternal Metabolic Factors and Early-Onset Puberty
www.prnewswire.com - April 16 at 3:58 AM
EXA (EXA) Downgraded to "Sell" at Zacks Investment ResearchEXA (EXA) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - April 7 at 3:53 PM
EXA (EXA) Rating Lowered to Sell at BidaskClubEXA (EXA) Rating Lowered to Sell at BidaskClub
www.americanbankingnews.com - April 1 at 2:04 PM
Examobile SA.’s (WSE:EXA) Earnings Dropped -54.75%, How Did It Fare Against The Industry?Examobile SA.’s (WSE:EXA) Earnings Dropped -54.75%, How Did It Fare Against The Industry?
finance.yahoo.com - March 29 at 10:24 AM
The Most Valuable Asset in Real Estate Could Be Your PhotographerThe Most Valuable Asset in Real Estate Could Be Your Photographer
www.prnewswire.com - March 28 at 4:08 AM
Glytec Announces Appointment of Ed Furlong as Chief Operating OfficerGlytec Announces Appointment of Ed Furlong as Chief Operating Officer
www.bizjournals.com - March 22 at 10:11 AM
Exactly when to buy plane tickets to get the best dealsExactly when to buy plane tickets to get the best deals
www.cnbc.com - March 21 at 10:22 AM
Dr. Shad Morris, DMD, Sets Example for Sleep Dentists Nationally in Former NFL Player Health AssessmentDr. Shad Morris, DMD, Sets Example for Sleep Dentists Nationally in Former NFL Player Health Assessment
www.prnewswire.com - March 21 at 4:39 AM
Death of the Mall? Greatly Exaggerated, Says Big MoneyDeath of the Mall? Greatly Exaggerated, Says Big Money
www.wsj.com - March 19 at 5:49 PM
Study Examines how Pharmaceutical Industry is Navigating New Scientific Publications LandscapeStudy Examines how Pharmaceutical Industry is Navigating New Scientific Publications Landscape
www.prnewswire.com - March 9 at 7:08 PM
Remarks from FDA Commissioner Scott Gottlieb, M.D., as prepared for oral testimony before the U.S. House Committee on Energy and Commerce Subcommittee on Oversight and Investigations hearing "Examining U.S. Public Health Preparedness for and ResponsRemarks from FDA Commissioner Scott Gottlieb, M.D., as prepared for oral testimony before the U.S. House Committee on Energy and Commerce Subcommittee on Oversight and Investigations hearing "Examining U.S. Public Health Preparedness for and Respons
www.prnewswire.com - March 8 at 12:23 PM
AT&T Connectivity Powers Dictum Healths Virtual Exam RoomAT&T Connectivity Powers Dictum Health's Virtual Exam Room
www.prnewswire.com - March 5 at 9:52 AM
Best Practices, LLC Report Examines How the Pharmaceutical Industry is Utilizing the Role of Medical Affairs to Enhance Payer InteractionsBest Practices, LLC Report Examines How the Pharmaceutical Industry is Utilizing the Role of Medical Affairs to Enhance Payer Interactions
www.prnewswire.com - March 2 at 6:48 PM
New Book Examines How Jesus of Nazareth Became Jesus the ProphetNew Book Examines How Jesus of Nazareth Became Jesus the Prophet
www.prnewswire.com - March 1 at 8:46 AM
Point of Care Diagnostics:  Good But Not Exaggerated Growth Next Five Years, ReportPoint of Care Diagnostics: Good But Not Exaggerated Growth Next Five Years, Report
www.prnewswire.com - February 28 at 11:13 PM
Exact Sciences (EXAS) a Buy at $44.37Exact Sciences (EXAS) a Buy at $44.37
investorplace.com - February 28 at 11:36 AM
New Exam Prep Tool Boosts National Mortgage Licensing Exam SuccessNew Exam Prep Tool Boosts National Mortgage Licensing Exam Success
www.prnewswire.com - February 22 at 8:51 AM
Definition of what’s actually an assault weapon is a highly contentious issueDefinition of what’s actually an 'assault weapon' is a highly contentious issue
www.cnbc.com - February 21 at 8:34 PM
Atlas API Training Develops Unique Audio Flash Cards to Complement Their Online Exam Prep Courses for Advanced Petrochemical Industry API CertificationsAtlas API Training Develops Unique Audio Flash Cards to Complement Their Online Exam Prep Courses for Advanced Petrochemical Industry API Certifications
www.prnewswire.com - February 21 at 5:12 AM
More Students Than Ever Are Participating And Succeeding In Advanced PlacementMore Students Than Ever Are Participating And Succeeding In Advanced Placement
www.prnewswire.com - February 21 at 1:27 AM
Radars And Weapons Global Market Report 2018Radars And Weapons Global Market Report 2018
www.prnewswire.com - February 12 at 11:51 AM
ExactRead -- Fengtao Softwares New Technology to Correct Read Errors Caused by Optical DrivesExactRead -- Fengtao Software's New Technology to Correct Read Errors Caused by Optical Drives
www.prnewswire.com - February 11 at 3:28 AM
Bloomberg Law Litigation Report Examines Drugmakers Unprecedented Patent Deal with American Indian TribeBloomberg Law Litigation Report Examines Drugmaker's Unprecedented Patent Deal with American Indian Tribe
www.prnewswire.com - February 8 at 10:00 AM
ROHMs New Boost Converter Provides 1.3x Longer Battery LifeROHM's New Boost Converter Provides 1.3x Longer Battery Life
feeds.benzinga.com - January 30 at 12:10 PM
Exact Sciences under modest pressure on new report from long-term bear Citron, shares down 3%Exact Sciences under modest pressure on new report from long-term bear Citron, shares down 3%
seekingalpha.com - January 25 at 2:34 PM
Colorectal Cancer Alliance-Funded Research among First to Examine Relationship between Colon Microbiota and Colorectal CancerColorectal Cancer Alliance-Funded Research among First to Examine Relationship between Colon Microbiota and Colorectal Cancer
www.prnewswire.com - January 23 at 6:23 AM
Exact Sciences under pressure on potential CRC blood screening test; shares down 9%Exact Sciences under pressure on potential CRC blood screening test; shares down 9%
seekingalpha.com - January 17 at 11:23 AM
Head to Head Survey: Attunity (ATTU) and EXA (EXA)Head to Head Survey: Attunity (ATTU) and EXA (EXA)
www.americanbankingnews.com - January 16 at 7:56 PM
Exa Corp (EXA) Receives Consensus Recommendation of "Hold" from BrokeragesExa Corp (EXA) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - January 16 at 4:02 AM
Exact Sciences Announces Upsize and Pricing of $600 Million of 1.0% Convertible Senior Notes Due 2025Exact Sciences Announces Upsize and Pricing of $600 Million of 1.0% Convertible Senior Notes Due 2025
www.prnewswire.com - January 11 at 10:20 PM
3 Slides That Paint a Great Picture for Exact Sciences Future3 Slides That Paint a Great Picture for Exact Sciences' Future
www.fool.com - January 10 at 9:19 AM
Global IoT Markets Dataset & Report 2017: Technologies & Market Forecasts up to 2030 - Examination of Market Trends in 14 Major VerticalsGlobal IoT Markets Dataset & Report 2017: Technologies & Market Forecasts up to 2030 - Examination of Market Trends in 14 Major Verticals
www.prnewswire.com - January 8 at 12:32 PM
Exact Sciences to report $265.5-266.5 million in revenue, 168 percent growth for 2017Exact Sciences to report $265.5-266.5 million in revenue, 168 percent growth for 2017
www.prnewswire.com - January 7 at 2:10 PM
The Cryptocurrency Market Isnt Fair, Which Is Exactly Why Its So Successful The Cryptocurrency Market Isn't Fair, Which Is Exactly Why It's So Successful
www.fool.com - January 6 at 12:53 PM
UPDATE - CCEI Offers No-Cost Online Course Examining The Mentoring Process: Developing Professionalism from WithinUPDATE - CCEI Offers No-Cost Online Course Examining The Mentoring Process: Developing Professionalism from Within
feeds.benzinga.com - January 3 at 12:26 PM
Pesquera Exalmar S.A.A. Announces Exchange Offer And Consent Solicitation For Any And All Of Its 7.375% Senior Notes Due 2020Pesquera Exalmar S.A.A. Announces Exchange Offer And Consent Solicitation For Any And All Of Its 7.375% Senior Notes Due 2020
www.prnewswire.com - December 22 at 8:13 PM
Exa Corp (EXA) Receives Consensus Rating of "Hold" from BrokeragesExa Corp (EXA) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - December 22 at 3:58 AM
New National Study Examines 2017 U.S. Physician Employment and Compensation GrowthNew National Study Examines 2017 U.S. Physician Employment and Compensation Growth
www.prnewswire.com - December 19 at 5:19 AM
République owners opening restaurant in downtown L.A.s historic Herald Examiner buildingRépublique owners opening restaurant in downtown L.A.'s historic Herald Examiner building
www.latimes.com - December 7 at 6:49 AM
500,000 New Biometric Drivers Licenses per Month500,000 New Biometric Driver's Licenses per Month
www.prnewswire.com - December 6 at 5:52 AM
500.000 novas carteiras de motorista com identificação biométrica por mês500.000 novas carteiras de motorista com identificação biométrica por mês
www.prnewswire.com - December 6 at 5:52 AM
Sino-British Academic Exchanges Take Step Forward in English AssessmentSino-British Academic Exchanges Take Step Forward in English Assessment
www.prnewswire.com - December 6 at 4:02 AM

SEC Filings

EXA (NASDAQ:EXA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

EXA (NASDAQ:EXA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

EXA (NASDAQ EXA) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.